Cargando…

Targeting of epigenetic regulators in neuroblastoma

Approximately 15,000 new cases of pediatric cancer are diagnosed yearly in Europe, with 8–10% corresponding to neuroblastoma, a rare disease with an incidence of 8–9 cases per million children <15 years of age. Although the survival rate for low-risk and intermediate-risk patients is excellent, h...

Descripción completa

Detalles Bibliográficos
Autores principales: Jubierre, Luz, Jiménez, Carlos, Rovira, Eric, Soriano, Aroa, Sábado, Constantino, Gros, Luis, Llort, Anna, Hladun, Raquel, Roma, Josep, Toledo, Josep Sánchez de, Gallego, Soledad, Segura, Miguel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938021/
https://www.ncbi.nlm.nih.gov/pubmed/29700278
http://dx.doi.org/10.1038/s12276-018-0077-2
_version_ 1783320722110676992
author Jubierre, Luz
Jiménez, Carlos
Rovira, Eric
Soriano, Aroa
Sábado, Constantino
Gros, Luis
Llort, Anna
Hladun, Raquel
Roma, Josep
Toledo, Josep Sánchez de
Gallego, Soledad
Segura, Miguel F.
author_facet Jubierre, Luz
Jiménez, Carlos
Rovira, Eric
Soriano, Aroa
Sábado, Constantino
Gros, Luis
Llort, Anna
Hladun, Raquel
Roma, Josep
Toledo, Josep Sánchez de
Gallego, Soledad
Segura, Miguel F.
author_sort Jubierre, Luz
collection PubMed
description Approximately 15,000 new cases of pediatric cancer are diagnosed yearly in Europe, with 8–10% corresponding to neuroblastoma, a rare disease with an incidence of 8–9 cases per million children <15 years of age. Although the survival rate for low-risk and intermediate-risk patients is excellent, half of children with high-risk, refractory, or relapsed tumors will be cured, and two-thirds of the other half will suffer major side effects and life-long disabilities. Epigenetic therapies aimed at reversing the oncogenic alterations in chromatin structure and function are an emerging alternative against aggressive tumors that are or will become resistant to conventional treatments. This approach proposes targeting epigenetic regulators, which are proteins that are involved in the creation, detection, and interpretation of epigenetic signals, such as methylation or histone post-translational modifications. In this review, we focused on the most promising epigenetic regulators for targeting and current drugs that have already reached clinical trials.
format Online
Article
Text
id pubmed-5938021
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59380212018-05-15 Targeting of epigenetic regulators in neuroblastoma Jubierre, Luz Jiménez, Carlos Rovira, Eric Soriano, Aroa Sábado, Constantino Gros, Luis Llort, Anna Hladun, Raquel Roma, Josep Toledo, Josep Sánchez de Gallego, Soledad Segura, Miguel F. Exp Mol Med Review Article Approximately 15,000 new cases of pediatric cancer are diagnosed yearly in Europe, with 8–10% corresponding to neuroblastoma, a rare disease with an incidence of 8–9 cases per million children <15 years of age. Although the survival rate for low-risk and intermediate-risk patients is excellent, half of children with high-risk, refractory, or relapsed tumors will be cured, and two-thirds of the other half will suffer major side effects and life-long disabilities. Epigenetic therapies aimed at reversing the oncogenic alterations in chromatin structure and function are an emerging alternative against aggressive tumors that are or will become resistant to conventional treatments. This approach proposes targeting epigenetic regulators, which are proteins that are involved in the creation, detection, and interpretation of epigenetic signals, such as methylation or histone post-translational modifications. In this review, we focused on the most promising epigenetic regulators for targeting and current drugs that have already reached clinical trials. Nature Publishing Group UK 2018-04-27 /pmc/articles/PMC5938021/ /pubmed/29700278 http://dx.doi.org/10.1038/s12276-018-0077-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, http://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Review Article
Jubierre, Luz
Jiménez, Carlos
Rovira, Eric
Soriano, Aroa
Sábado, Constantino
Gros, Luis
Llort, Anna
Hladun, Raquel
Roma, Josep
Toledo, Josep Sánchez de
Gallego, Soledad
Segura, Miguel F.
Targeting of epigenetic regulators in neuroblastoma
title Targeting of epigenetic regulators in neuroblastoma
title_full Targeting of epigenetic regulators in neuroblastoma
title_fullStr Targeting of epigenetic regulators in neuroblastoma
title_full_unstemmed Targeting of epigenetic regulators in neuroblastoma
title_short Targeting of epigenetic regulators in neuroblastoma
title_sort targeting of epigenetic regulators in neuroblastoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938021/
https://www.ncbi.nlm.nih.gov/pubmed/29700278
http://dx.doi.org/10.1038/s12276-018-0077-2
work_keys_str_mv AT jubierreluz targetingofepigeneticregulatorsinneuroblastoma
AT jimenezcarlos targetingofepigeneticregulatorsinneuroblastoma
AT roviraeric targetingofepigeneticregulatorsinneuroblastoma
AT sorianoaroa targetingofepigeneticregulatorsinneuroblastoma
AT sabadoconstantino targetingofepigeneticregulatorsinneuroblastoma
AT grosluis targetingofepigeneticregulatorsinneuroblastoma
AT llortanna targetingofepigeneticregulatorsinneuroblastoma
AT hladunraquel targetingofepigeneticregulatorsinneuroblastoma
AT romajosep targetingofepigeneticregulatorsinneuroblastoma
AT toledojosepsanchezde targetingofepigeneticregulatorsinneuroblastoma
AT gallegosoledad targetingofepigeneticregulatorsinneuroblastoma
AT seguramiguelf targetingofepigeneticregulatorsinneuroblastoma